Management ChangeJun 4, 2026, 04:38 PM
Tempest Therapeutics Appoints Two Independent Directors
AI Summary
Tempest Therapeutics announced the appointment of Drake Richey and John Yee, MD, MPH, as independent directors to its Board of Directors, effective June 4, 2026. Mr. Richey brings extensive experience in corporate finance, while Dr. Yee contributes decades of expertise in therapeutic product development. The company's President and CEO, Matt Angel, Ph.D., stated that their addition would further enable Tempest to achieve its vision of providing meaningful treatment options to cancer patients and support the company's focus on growth and capital allocation.
Key Highlights
- Tempest Therapeutics appointed Drake Richey as an independent director.
- Drake Richey brings decades of experience in corporate finance.
- Tempest Therapeutics appointed John Yee, MD, MPH, as an independent director.
- Dr. Yee brings decades of experience in therapeutic product development.
- The new directors are expected to support growth and disciplined capital allocation.
- The appointments are effective June 4, 2026.
Price Impact
More from TPST